Latest News

Interim Results for the Six Months Ended 30 June 2020

30 September 2020

London, 30 September 2020 – Tiziana Life Sciences plc (“Tiziana”, AIM: TILS, NASDAQ: TLSA), a biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases today announces its interim results for the six months ended 30 June 2020.

Read more

Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money Report

25 September 2020

Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money Report

Read more

Issue of Equity and Total Voting Rights

21 September 2020

London, New York, 21 September 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has allotted and...

Read more

Tiziana to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil

17 September 2020

Nasal Administration of Foralumab is a potentially transformative approach for treating patients with Covid-19.

New York/London, September 17, 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for...

Read more

Tiziana Life Sciences Announces Planned Spin Out of StemPrintER into a New Publicly Listed Company, AccuStem Sciences

16 September 2020

Tiziana Shareholders to receive 1:1 share dividend in AccuStem Sciences

NEW YORK/LONDON, September 16, 2020 Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases...

Read more

TR-1: Standard form for notification of major holdings

28 August 2020


NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

...

Read more

Page 1 of 20 Next